TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26275982

Group type: EXPERIMENTAL
Intervention: Beta blockers (metoprolol and carvedilol)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Calcium channel blockers (diltiazem and verapamil)
Number of subjects: 60
Study: 24124709

Group type: EXPERIMENTAL
Intervention: ICP plus PbtO2 monitoring
Number of subjects: 46

Group type: COMPARATOR
Intervention: ICP monitoring alone (Control)
Number of subjects: 46
Study: 21132360

Group type: EXPERIMENTAL
Intervention: E (100 mg/m² i.v. d1, q21 days for 4 cycles) followed by CMF (600, 40, 600 mg/m² i.v. d1 and 8, q28 days for 4 cycles)
Number of subjects: 1066

Group type: EXPERIMENTAL
Intervention: CMF followed by E
Number of subjects: 1066

Group type: COMPARATOR
Intervention: E → CMF and CMF → E
Number of subjects: 1066

Group type: COMPARATOR
Intervention: CMF → E
Number of subjects: 1066
Study: 18166089

Group type: EXPERIMENTAL
Intervention: Injectable calcium phosphate bone cement (CPC)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Open flap debridement (OFD)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: CPC-R group (CPC with no adverse reactions)
Number of subjects: 30
Study: 16324851

Group type: EXPERIMENTAL
Intervention: Concentric training at 30 degrees/s
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Concentric training at 90 degrees/s
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Eccentric training
Number of subjects: 55
Study: 15162243

Group type: EXPERIMENTAL
Intervention: HT-EIH
Number of subjects: 29

Group type: COMPARATOR
Intervention: HT-nEIH
Number of subjects: 29

Group type: COMPARATOR
Intervention: UT
Number of subjects: 29
Study: 11317536

Group type: EXPERIMENTAL
Intervention: Live tularemia vaccine
Number of subjects: 0
Study: 9039083

Group type: EXPERIMENTAL
Intervention: Human brain natriuretic peptide-32 at a dose of 4 pmol/kg per minute
Number of subjects: 5

Group type: COMPARATOR
Intervention: 5% dextrose infusion (control)
Number of subjects: 5
Study: 8284070

Group type: EXPERIMENTAL
Intervention: Meclofenamate 50 mg
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: Meclofenamate 100 mg
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: Ibuprofen 200 mg
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg
Number of subjects: 254

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: Meclofenamate (multidose phase)
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: Ibuprofen (multidose phase)
Number of subjects: 254
Study: 3443139

Group type: EXPERIMENTAL
Intervention: Prazosin (n = 40, 1.5‐12.0 mg per day)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Propranolol (n = 30, 30‐120 mg per day)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Switch from Propranolol to Prazosin
Number of subjects: 70
Study: 31667680

Group type: EXPERIMENTAL
Intervention: Inpatients
Number of subjects: 398

Group type: COMPARATOR
Intervention: Internet users
Number of subjects: 398

Group type: EXPERIMENTAL
Intervention: Overall participants
Number of subjects: 398
Study: 30526548

Group type: EXPERIMENTAL
Intervention: Lung Ultrasound (LUS)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Lung Ultrasound (LUS) with consolidation > 1 cm
Number of subjects: 87

Group type: COMPARATOR
Intervention: Chest X-ray (CXR)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Inter-observer agreement between pediatrician and radiologist
Number of subjects: 87
Study: 27564857

Group type: EXPERIMENTAL
Intervention: Monitored activity data provision to patients and clinicians with explicit goal setting
Number of subjects: 255

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: Monitored activity data provision to patients and clinicians
Number of subjects: 255
Study: 25034127

Group type: EXPERIMENTAL
Intervention: allele-specific PCR (AS-PCR)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: ultra-deep pyrosequencing
Number of subjects: 105
Study: 22764608

Group type: EXPERIMENTAL
Intervention: OVR simulation (galvanic vestibular stimulation)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control (no OVR simulation)
Number of subjects: 21
Study: 20559708

Group type: EXPERIMENTAL
Intervention: Doxorubicin (60 mg/m²) plus Cyclophosphamide (600 mg/m²) every 3 weeks (AC)
Number of subjects: 363

Group type: COMPARATOR
Intervention: Doxorubicin (50 mg/m²) plus Docetaxel (75 mg/m²) every 3 weeks (AD)
Number of subjects: 363

Group type: EXPERIMENTAL
Intervention: Doxorubicin and Cyclophosphamide (AC)
Number of subjects: 363

Group type: COMPARATOR
Intervention: Doxorubicin and Docetaxel (AD)
Number of subjects: 363
Study: 18481035

Group type: EXPERIMENTAL
Intervention: 15 mg l-amphetamine
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: 30 mg l-amphetamine
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: 45 mg l-amphetamine
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 16162746

Group type: EXPERIMENTAL
Intervention: Anticoagulant therapy (oral warfarin and low-molecular-weight heparin) plus prednisolone
Number of subjects: 56

Group type: COMPARATOR
Intervention: Prednisolone alone (non-anticoagulant group)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Anticoagulant therapy (during acute exacerbation)
Number of subjects: 56
Study: 12881333

Group type: EXPERIMENTAL
Intervention: Latanoprost
Number of subjects: 48

Group type: COMPARATOR
Intervention: Isopropyl unoprostone
Number of subjects: 48
Study: 10208214

Group type: EXPERIMENTAL
Intervention: MIPuni
Number of subjects: 54

Group type: COMPARATOR
Intervention: MIPbest
Number of subjects: 54
Study: 7778637

Group type: EXPERIMENTAL
Intervention: Intravaginal misoprostol (25 micrograms every 3 hours, max 8 doses)
Number of subjects: 276

Group type: COMPARATOR
Intervention: Intracervical dinoprostone (0.5 mg every 6 hours, max 3 doses)
Number of subjects: 276

Group type: COMPARATOR
Intervention: Intracervical dinoprostone
Number of subjects: 276

Group type: EXPERIMENTAL
Intervention: Intravaginal misoprostol
Number of subjects: 276
Study: 2803413

Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo device
Number of subjects: 34
Study: 31877968

Group type: EXPERIMENTAL
Intervention: Brazil nut oil (BNO), 10 mL daily for 30 days
Number of subjects: 31

Group type: COMPARATOR
Intervention: Soybean oil (SO), 10 mL daily for 30 days
Number of subjects: 31
Study: 28573246

Group type: EXPERIMENTAL
Intervention: Body Awareness Therapy (BAT)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Aerobic Exercises
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study: 26152421

Group type: EXPERIMENTAL
Intervention: Toltrazuril (15 mg/kg)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study: 23703422

Group type: EXPERIMENTAL
Intervention: Tapentadol IR (50, 75, or 100 mg)
Number of subjects: 645

Group type: COMPARATOR
Intervention: Oxycodone IR (5, 10, or 15 mg)
Number of subjects: 645

Group type: EXPERIMENTAL
Intervention: Tapentadol IR
Number of subjects: 645

Group type: COMPARATOR
Intervention: Oxycodone IR
Number of subjects: 645
Study: 21839452

Group type: EXPERIMENTAL
Intervention: Inside-out TO-TVT
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Outside-in TO-TVT
Number of subjects: 224
Study: 18760637

Group type: EXPERIMENTAL
Intervention: ACL reconstruction followed by a structured rehabilitation program
Number of subjects: 58

Group type: COMPARATOR
Intervention: Structured rehabilitation only
Number of subjects: 58
Study: 17725931

Group type: EXPERIMENTAL
Intervention: Smoking videos (12 videos containing cigarette smoking scenes)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Neutral videos (12 videos containing neutral scenes)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Self-reported craving (0-100 scale) after smoking videos
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Galvanic skin response after smoking videos
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Skin temperature after smoking videos
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Blood pressure response after smoking videos
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Skin temperature response after smoking videos
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Responses to videos of women smoking vs. men smoking
Number of subjects: 20
Study: 15282383

Group type: EXPERIMENTAL
Intervention: 500 mg natural vitamin E for 6 weeks
Number of subjects: 72

Group type: COMPARATOR
Intervention: Matched placebo for 6 weeks
Number of subjects: 72
Study: 11317052

Group type: EXPERIMENTAL
Intervention: Ventilation techniques that avoid intubation and ventilation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Strategies that maintain the lung open and minimize tidal volumes
Number of subjects: 0

Group type: COMPARATOR
Intervention: Postnatal steroids
Number of subjects: 0
Study: 9754590

Group type: EXPERIMENTAL
Intervention: Forearm exercise training (30 minutes of handgrip exercise four times a week for 4-6 weeks)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control subjects (no intervention)
Number of subjects: 18
Study: 7824863

Group type: EXPERIMENTAL
Intervention: 20 g lactulose ingestion in methane producers
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 10 g, 20 g, and 30 g lactulose ingestion
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Methane producers
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Methane and hydrogen excretion measurements
Number of subjects: 14
Study: 3780236

Group type: EXPERIMENTAL
Intervention: Ortho Creme
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Gynol II
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo jelly
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo creme
Number of subjects: 12
Study: 30526031

Group type: EXPERIMENTAL
Intervention: Cook Flexor™ sheath
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Boston Scientific Navigator HD™ sheath
Number of subjects: 95

Group type: COMPARATOR
Intervention: Both sheaths
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Subjectively difficult sheath placement and longer time of placement
Number of subjects: 95
Study: 29772084

Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate (TDF)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Entecavir (ETV)
Number of subjects: 45
Study: 27285345

Group type: EXPERIMENTAL
Intervention: Combined aerobic-resistance exercise therapy (3 weekly sessions of 60 minutes for 12 weeks)
Number of subjects: 43

Group type: COMPARATOR
Intervention: No exercise control group
Number of subjects: 43
Study: 24686284

Group type: EXPERIMENTAL
Intervention: Food-related motivation measures using handgrip force as a motivational measure.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Metabolic (satiety) and pharmacological manipulations.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Willingness to pay as a metric for reward goal values.
Number of subjects: 0
Study: 22018769

Group type: EXPERIMENTAL
Intervention: Collaborative depression care
Number of subjects: 2821
Study: 20593498

Group type: EXPERIMENTAL
Intervention: Cetuximab + FOLFOX6 (arm A)
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Cetuximab + FOLFIRI (arm B)
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: KRAS wild-type tumors (arm A)
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: KRAS wild-type tumors (arm B)
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: KRAS mutated tumors (arm A)
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: KRAS mutated tumors (arm B)
Number of subjects: 151
Study: 18676556

Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin
Number of subjects: 0

Group type: COMPARATOR
Intervention: NaCl 0.9% (placebo)
Number of subjects: 0
Study: 18569647

Group type: EXPERIMENTAL
Intervention: Voice Training (VT)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Voice Hygiene Lecture (VHL)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study: 15213045

Group type: EXPERIMENTAL
Intervention: Plant free sterols
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Plant sterol esters
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control (low-fat milk-based beverage alone)
Number of subjects: 26
Study: 11284816

Group type: EXPERIMENTAL
Intervention: Vecuronium
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Atracurium
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Rocuronium
Number of subjects: 150

Group type: COMPARATOR
Intervention: No neuromuscular blocking drugs
Number of subjects: 150
Study: 9393381

Group type: EXPERIMENTAL
Intervention: Estrogen replacement therapy
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Estrogen use (observational studies)
Number of subjects: 19
Study: 8144294

Group type: EXPERIMENTAL
Intervention: Milk vitamin A per gram milk fat
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Milk vitamin A concentration
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Serum retinol concentration
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Milk indicators
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Milk vitamin A
Number of subjects: 0
Study: 3611943

Group type: EXPERIMENTAL
Intervention: Fat clearance technique
Number of subjects: 20

Group type: COMPARATOR
Intervention: Manual dissection method
Number of subjects: 20

Group type: COMPARATOR
Intervention: Comparison of both methods
Number of subjects: 20
Study: 31620815

Group type: EXPERIMENTAL
Intervention: D-VMP
Number of subjects: 91

Group type: COMPARATOR
Intervention: VMP
Number of subjects: 91
Study: 27694633

Group type: EXPERIMENTAL
Intervention: RSV-PreF vaccine with 10 µg
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: RSV-PreF vaccine with 30 µg and alum adjuvant
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: RSV-PreF vaccine with 60 µg and alum adjuvant
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: RSV-PreF vaccine with 60 µg and nonadjuvant
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: RSV-PreF vaccine (all dosages)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 128
Study: 24409937

Group type: EXPERIMENTAL
Intervention: Continuous curvilinear capsulorhexis (CCC) using an irrigation‐aspiration system by a phaco machine in Group 1 (27 eyes)
Number of subjects: 50

Group type: COMPARATOR
Intervention: CCC using an ocular visco‐elastic device (OVD) and utrata forceps in Group 2 (26 eyes)
Number of subjects: 50
Study: 23165609

Group type: EXPERIMENTAL
Intervention: Exercise training (Ex)
Number of subjects: 351

Group type: EXPERIMENTAL
Intervention: Isoflavone supplementation (Iso: 165 mg/d)
Number of subjects: 351

Group type: EXPERIMENTAL
Intervention: Combined exercise and isoflavone (ExIso)
Number of subjects: 351

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 351
Study: 21372654

Group type: EXPERIMENTAL
Intervention: Pregabalin 150 mg
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Pregabalin 75 mg
Number of subjects: 84

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study: 19693532

Group type: EXPERIMENTAL
Intervention: Healthy runners
Number of subjects: 18

Group type: COMPARATOR
Intervention: Illness-prone runners
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 18
Study: 16887418

Group type: EXPERIMENTAL
Intervention: Chelation therapy with edetate calcium disodium (EDTA) for 3 months and repeated therapy to maintain BLB below 20 microg
Number of subjects: 108

Group type: COMPARATOR
Intervention: Placebo therapy
Number of subjects: 108
Study: 15251637

Group type: EXPERIMENTAL
Intervention: Continuous intravenous insulin (CII) therapy
Number of subjects: 4864

Group type: COMPARATOR
Intervention: Hyperglycemia
Number of subjects: 4864
Study: 11738907

Group type: EXPERIMENTAL
Intervention: Bandage soft contact lens (BSCL)
Number of subjects: 120

Group type: COMPARATOR
Intervention: No bandage soft contact lens (no BSCL)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Tetracaine 0.5%
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Voltaren (diclofenac sodium 0.1%)
Number of subjects: 120
Study: 9257204

Group type: EXPERIMENTAL
Intervention: Flexor hallucis brevis
Number of subjects: 10

Group type: COMPARATOR
Intervention: Adductor pollicis
Number of subjects: 10
Study: 8300044

Group type: EXPERIMENTAL
Intervention: recombinant human growth hormone (rhGH)
Number of subjects: 11
Study: 3747484

Group type: EXPERIMENTAL
Intervention: Health education
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Exercise plus health education
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control
Number of subjects: 52
Study: 29126078

Group type: EXPERIMENTAL
Intervention: Sunflower oil massage (moderate pressure)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Routine NICU care (Control)
Number of subjects: 44
Study: 27507007

Group type: EXPERIMENTAL
Intervention: Aerobic exercise program (12 weeks)
Number of subjects: 49
Study: 24373823

Group type: EXPERIMENTAL
Intervention: Boron neutron capture therapy with Na2B12H11SH (BSH)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Boron neutron capture therapy with p‐dihydroxyborylphenylalanine (BPA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Radiotherapy with temozolomide
Number of subjects: 0
Study: 23093273

Group type: EXPERIMENTAL
Intervention: Fenofibrate
Number of subjects: 9522

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9522
Study: 20213817

Group type: EXPERIMENTAL
Intervention: Bilateral subthalamic nucleus (STN) deep brain stimulation (DBS)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Bilateral globus pallidus internus (GPi) deep brain stimulation (DBS)
Number of subjects: 51
Study: 17803837

Group type: EXPERIMENTAL
Intervention: Collaborative care (case manager-coordinated medication support and brief psychological treatment, enhanced specialist and GP communication)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Collaborative care
Number of subjects: 114

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 114
Study: 15601269

Group type: EXPERIMENTAL
Intervention: Intravenous infusion of ephedrine
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Intravenous infusion of mephentermine
Number of subjects: 60
Study: 12227391

Group type: EXPERIMENTAL
Intervention: Vancomycin 1 g/L intraperitoneally as loading dose, repeated on day 5 or day 8 for 2 weeks.
Number of subjects: 30

Group type: COMPARATOR
Intervention: Cefazolin 1 g in the first PD bag and continued with 125 mg/L every exchange for 2 or 3 weeks, depending on culture results.
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Vancomycin
Number of subjects: 30

Group type: COMPARATOR
Intervention: Cefazolin
Number of subjects: 30
Study: 9708650

Group type: EXPERIMENTAL
Intervention: tissue plasminogen activator (t‐PA) therapy within 2 hours of acute symptom onset
Number of subjects: 71253

Group type: COMPARATOR
Intervention: tissue plasminogen activator (t‐PA) therapy after 2 hours
Number of subjects: 71253

Group type: EXPERIMENTAL
Intervention: tissue plasminogen activator (t‐PA) therapy
Number of subjects: 71253
Study: 8751015

Group type: EXPERIMENTAL
Intervention: lisinopril
Number of subjects: 12

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study: 2095291

Group type: EXPERIMENTAL
Intervention: Diazepam (5 mg), administered 2 hours after reading the text
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Naltrexone (50 mg), administered before reading the text
Number of subjects: 88

Group type: COMPARATOR
Intervention: Placebo, administered before reading the text
Number of subjects: 88

Group type: COMPARATOR
Intervention: Placebo, administered 2 hours after reading the text
Number of subjects: 88
Study: 668776

Group type: EXPERIMENTAL
Intervention: Activated charcoal 50 g suspended in water
Number of subjects: 6
Study: 31742823

Group type: EXPERIMENTAL
Intervention: EMC2 intervention
Number of subjects: 652

Group type: EXPERIMENTAL
Intervention: EMC2 + SMS intervention
Number of subjects: 652

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 652
Study: 28219430

Group type: EXPERIMENTAL
Intervention: Digital health system (tablet computer and pulse oximeter)
Number of subjects: 110
Study: 26539764

Group type: EXPERIMENTAL
Intervention: COSS (new organizational return-to-work intervention)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Common practice (control)
Number of subjects: 0
Study: 23089685

Group type: EXPERIMENTAL
Intervention: Home visits by nurses about 48‐72 hours after discharge
Number of subjects: 71

Group type: COMPARATOR
Intervention: Conventional care
Number of subjects: 71
Study: 21832184

Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation (TMS) applied during saccadic eye movements
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation (TMS) applied during coordinated movements of both eyes and lids
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation (TMS) applied repeatedly
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation (TMS) during pro-saccades and anti-saccades
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation (TMS) affecting ongoing motor commands
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation (TMS) and internal feedback correction
Number of subjects: 0
Study: 19210949

Group type: EXPERIMENTAL
Intervention: Brief cognitive-behavioral therapy (CBT) delivered by mental health nurses trained over 10 days with ongoing supervision
Number of subjects: 422

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 422

Group type: EXPERIMENTAL
Intervention: Brief cognitive-behavioral therapy (CBT)
Number of subjects: 422
Study: 17118092

Group type: EXPERIMENTAL
Intervention: Chewing (tasteless and odorless substance for 15 min each hour)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14

Group type: COMPARATOR
Intervention: Caffeine (200 mg)
Number of subjects: 14
Study: 14975603

Group type: EXPERIMENTAL
Intervention: Interferon-beta 1b treatment
Number of subjects: 29
Study: 11598620

Group type: EXPERIMENTAL
Intervention: Muscle sympathetic nerve activity (MSA) in LSCS patients
Number of subjects: 12

Group type: COMPARATOR
Intervention: Muscle sympathetic nerve activity (MSA) in normal subjects
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Sensory nerve conduction velocity (SNCV) in LSCS patients
Number of subjects: 12

Group type: COMPARATOR
Intervention: Sensory nerve conduction velocity (SNCV) in normal subjects
Number of subjects: 12